Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 5/20 | 0.35 |
| ▸ | PLG | P00747 | 9/20 | 0.35 |
| ▸ | PLAU | P00749 | 9/20 | 0.35 |
| ▸ | ITGAV | P06756 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462974 | 0.86 | ITGB3 (0.38) | ITGB3ITGA2BITGAVHTT | |
| SCHEMBL4464577 | 0.81 | ALDH1A1 (0.38) | ITGB3ITGA2BITGAVHTT | |
| SCHEMBL4452679 | 0.81 | CTSB (0.32) | ITGB3ITGA2BITGAV | |
| SCHEMBL3747259 | 0.78 | F10 (0.58) | F10PLGPLAUF2ST14 | |
| SCHEMBL4450993 | 0.70 | ADAMTS4 (0.44) | HTT | |
| SCHEMBL4556596 | 0.70 | PLAU (0.41) | ITGB3ITGA2BF10PLGPLAU | |
| SCHEMBL4557815 | 0.66 | ITGB3 (0.42) | ITGB3ITGA2BF10PLGPLAU | |
| SCHEMBL6551536 | 0.63 | THRA (0.31) | — | |
| SCHEMBL4457655 | 0.62 | KEAP1 (0.32) | — | |
| SCHEMBL7521219 | 0.61 | F10 (0.50) | ITGB3ITGA2BF10PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | PLAU, PLAUR, ENPEP | ITGB3 2345/4885ITGA2B 4012/4885F10 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.